Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants

Publication Date

2016

Journal Title

J Thromb Thrombolysis

Abstract

Although there is controversy about the absolute need for a reversal agent for the new direct oral anticoagulants (DOACs), the absence of such an agent is a barrier to more widespread use of these agents. For the management of major life-threatening bleeding with the DOACs, most authorities recommend the use of four factor prothrombin complex concentrates, although the evidence to support their use in terms of improving outcomes is meager. At the present time, there are three antidotes in development and poised to enter the market. Idarucizumab is a drug-specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran. Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. Ciraparantag is a universal antidote targeted to reverse the direct thrombin and factor Xa inhibitors as well as the indirect inhibitor, enoxaparin.

Volume Number

41

Issue Number

2

Pages

248-52

Document Type

Article

EPub Date

2015/10/10

Status

Faculty

Facility

School of Medicine

Primary Department

General Internal Medicine

PMID

26449414

DOI

10.1007/s11239-015-1288-1

For the public and Northwell Health campuses

Share

COinS